Back to discover
Disease

Chickenpox

Late-stage therapeutic developmentEmerging research
MeSHChickenpox
1
Publications
14
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones6View
Results expected 5
Recently completed 1
Activity timeline6

Clinical trials

8 sponsors · 3 new · 0 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
14
All trials
6
Active
11
Late-stage
6
Completed
Late-stage studies

A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Phase 3 · Recruiting · GC Biopharma Corp

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

Immunogenicity and Safety of the Second Dose of Varicella Vaccine in Healthy Children: An Open-label Study

Phase 3 · Recruiting · Sinovac (Dalian) Vaccine Technology Co., Ltd.

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Phase 3 · Recruiting · GlaxoSmithKline
Recruiting

A Phase III, Double-blind, Randomized, Multicenter, Multinational, Active-controlled, Non-inferiority Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Phase 3 · Recruiting · GC Biopharma Corp

A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

Immunogenicity and Safety of the Second Dose of Varicella Vaccine in Healthy Children: An Open-label Study

Phase 3 · Recruiting · Sinovac (Dalian) Vaccine Technology Co., Ltd.

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

Phase 3 · Recruiting · GlaxoSmithKline

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Phase 3 · Recruiting · GlaxoSmithKline
Recently completed

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

Phase 2 · Completed · GlaxoSmithKline

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Adolescents and Adults Aged Between 13 to 55 Years : a Double-Blind, Randomized, Parallel-Controlled Phase III Clinical Trial in China

Phase 3 · Completed · Southeast University, China

Phase III Clinical Trial of Lyophilized Live Attenuated Varicella Vaccine for Children Aged 1-12 Years

Phase 3 · Completed · Southeast University, China

A Cross-over, Open-label, Single-group Study to Evaluate the Safety and Immunogenicity of Live Attenuated Varicella Vaccine Skyvaricella Injection (Inj.) Developed by SK Bioscience (Company Limited) Co., Ltd of South Korea in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old

Phase 4 · Completed · Vietnam Military Medical University

A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

Phase 4 · Completed · Changchun Keygen Biological Products Co., Ltd.

Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin

Phase 4 · Completed · Beijing Center for Disease Control and Prevention

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Manipulation of the Innate Immune Response by Varicella Zoster Virus.

Frontiers in immunology · 2020 · 78 cites
Recent publications

Manipulation of the Innate Immune Response by Varicella Zoster Virus.

Frontiers in immunology · 2020 · 78 cites
Major themes1
  • Immunity, Innate1
Leading journals1
  • Frontiers in immunology1
Leading researchers7
  • Abendroth A1
  • Campbell TM1
  • Gerada C1
  • Kennedy JJ1
  • McSharry BP1
  • Slobedman B1
  • Steain M1
Affiliations (unnormalised)1
  • Charles Perkins Centre1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed)

Identifiers
MeSHChickenpox
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.